Daily Archives: March 21, 2021

Borracchinis Bakery permanently closed after 100 years in Seattle due to COVID-19 – KING5.com

Posted: March 21, 2021 at 5:07 pm

Borracchinis Bakery, which has served up cakes and Italian delicacies for 100 years, is going out of business.

SEATTLE Seattle is losing another institution as Borracchinis Bakery announced Saturday it would remain permanently closed due to financial losses from the COVID-19 pandemic.

Months of no gatherings, weddings or parties proved to be too much for the iconic Italian deli, which shut its doors after 100 years in business.

Needless to say, it was devastating to our business, the Borracchini family wrote in a Facebook post.

As COVID-19 restrictions tightened and loosened over the last year, the bakery temporarily closed in March and reopened in summer before closing "until further notice" after new restrictions were put in place in November.

The bakery thanked customers and staff, who the Borracchini family said were like our extended family.

You all have given us a lifetime of memories that will never be forgotten, the Borracchinis wrote. It has been a privilege to be a part of all of your birthdays, anniversaries and important lifetime celebrations.

After the bakery announced the closure on Facebook, within four hours more than 1,000 people commented, sharing memories of weddings, birthdays and important milestones supplied by Borracchini's.

The beloved bakery was featured in the childrens book A Ticket to the Pennant: A Tale of Baseball in Seattle, by Mark Holtzen, which was set in 1955 in Seattle.

The Associated Press contributed.

Read the original:

Borracchinis Bakery permanently closed after 100 years in Seattle due to COVID-19 - KING5.com

Posted in Covid-19 | Comments Off on Borracchinis Bakery permanently closed after 100 years in Seattle due to COVID-19 – KING5.com

What can you do after getting the COVID-19 vaccine? Here’s how Alaska’s top public health experts are adjusting. – Anchorage Daily News

Posted: at 5:07 pm

A year after the first coronavirus case was identified in the state, more and more Alaskans have received the COVID-19 vaccine, signaling a hopeful turning point in the pandemic.

By Friday, 206,877 people about 36% of Alaskans eligible for a shot had received at least their first dose, according to the states vaccine monitoring dashboard. At least 144,644 people about 25% of Alaskans 16 and older were considered fully vaccinated.

Now some newly vaccinated Alaskans are wondering: Whats safe and what isnt?

We spoke with some top public health officials in Alaska to see how theyre navigating life after vaccination a situation more residents are experiencing.

Most health officials said they were still cautious and still wearing their masks, and they believed the pandemic wasnt over just yet. They reflected on small moments of joy that they say wouldnt have been possible prior to getting vaccinated. They conveyed a sense of hope and relief that has accompanied their new status.

All had closely followed the new guidance recently issued by the Centers for Disease Control and Prevention, about what fully vaccinated people can and cant do. The CDC considers individuals to be fully vaccinated once two weeks have passed since they received a second dose of the Moderna or Pfizer vaccine, or a single dose of the Johnson & Johnson vaccine.

People approach their turn to receive a vaccination in their cars at Dempsey Anderson Ice Arena in Anchorage on Friday, March 19, 2021. (Anne Raup / ADN)

Additionally, the CDC says its OK for vaccinated people to visit an unvaccinated household indoors as long as none of the unvaccinated people are at a high risk for severe illness from the virus due to their age or health, since the data on whether the vaccines entirely prevent asymptomatic spread is still incomplete.

But on some issues, the agencys recommendations remain vague or cautious: For example, the CDC continues to recommend against medium or large-sized gatherings, but doesnt define what constitutes a gathering of each size.

The CDC is also still recommending against nonessential travel and encouraging mask-wearing and social distancing when possible, noting that its still learning how vaccines will affect the spread of COVID-19.

All of the Alaska health officials the Daily News spoke with said they hoped the CDC would clarify and expand some of its recommendations soon.

Last weekend, Dr. Anne Zink went inside a shop to get her bike fixed something that she would have avoided prior to get vaccinated.

So although it was a small thing, it was just great to see everyone again, and to laugh and to hear what their lives have been like and to get that fixed, she said. A little boring errand ended up being a great joy.

Zink, Alaskas top doctor, became a household name this year, known for her role helping lead the states coronavirus response.

She has been fully vaccinated for about two months, and she said it feels a little like rock climbing with a rope to catch her fall.

Pre-vaccination was like solo free climbing, without a safety net, and trying to make your best decisions as you can, she said. And now it feels kind of like youre top-roping. Its not perfect rocks can still fall, things can still happen. But it just feels like theres a really significant added level of protection.

Zink said shes still been cautious even after receiving the vaccine: She still wears her mask when shes in public, avoids large gatherings and hasnt eaten out at a restaurant, yet. Case counts in Anchorage and other parts of the state are still high, she pointed out. But in many small ways, life feels different.

She has also started hugging her fully vaccinated friends, and she said she feels good about getting haircuts and other one-on-one indoor interactions where both people are wearing a mask.

Zinks still having a little trouble adjusting to the possibility of having vaccinated friends come over to her house, even though the CDC says thats allowable. On the other hand, she said shes also struggling with the CDCs recommendation on traveling which is still to postpone nonessential travel, even if youre vaccinated.

I think that post-vaccine, particularly while while wearing good protection while flying, doesnt seem as high risk, she said. She misses her now fully vaccinated parents, who live in Colorado, and hopes to be able to visit them soon.

I have not seen them during this whole pandemic, and theyre getting older, she said. So I am really looking forward to traveling.

Buttons reading, I am vaccinated against COVID-19 , rest in a bag on a table at the Blood Bank of Alaska in Anchorage on March 10, 2021. (Emily Mesner / ADN)

Joe McLaughlin, an epidemiologist with the state, has been fully vaccinated for a couple weeks.

Its a real relief, he said. I think weve all been struggling with isolation. And to be able to interact with your family and friends in a way you havent been able to do for the last year, it just feels great.

For McLaughlin, many of the joys of being vaccinated show up in quiet moments. One recent afternoon, he left work midday to go skiing at Arctic Valley Ski Area for the first time this winter.

I was so excited to get to ski and get a ride up the mountain, and to ski down, he said. I would have not done that prior to getting vaccinated, I would have thought that was too high risk.

Hes also been feeling more comfortable getting outside and exercising with a small group of friends, especially the ones who are fully vaccinated, and having a small number of vaccinated friends over for dinner.

There are a few things hed like to do but doesnt feel quite ready for yet. He wants to visit his fully vaccinated parents in Florida but thinks the potential risk of picking up the virus while traveling is too great at this time.

I know these vaccines are incredibly effective, around 95% effective for the two mRNA vaccines from Pfizer and Moderna, he said. But that still means theres a 5% chance of getting infected, and I wouldnt want to risk that for my parents who are both older and at an elevated risk.

Hes also not comfortable gathering in groups of larger than 10, or eating out at a restaurant.

I dont plan on (eating out) anytime real soon, he said. I know some people may feel comfortable doing that, and I respect that. But I personally feel like I want to wait until our case counts drop more, and we get higher vaccine coverage rates.

A woman waits in the monitoring area at the Blood Bank of Alaska after receiving a COVID-19 vaccine in Anchorage on March 10, 2021. (Emily Mesner / ADN)

Getting vaccinated was surprisingly emotional, said Dr. Ellen Hodges, chief of staff for the Yukon Kuskokwim Health Corp., a tribal health organization that serves a primarily roadless region of Southwest Alaska.

The vaccine represents protection against a virus responsible for a massive outbreak in the region, Hodges said. And it means protection for her as well as the people she works with.

One of the things thats hard about having providers that work for you is that youre asking them to expose themselves and take risks, Hodges said. And you didnt have really anything except for a mask to protect them.

The biggest change for Hodges post-vaccination was the ability to get together with small groups of friends or family and not have the gathering be dangerous, Hodges said.

But that doesnt mean it felt normal initially.

After months of masking and social distancing, her first dinner with two others felt weird.

The whole time, it didnt feel quite real almost, Hodges said. They were eating together, unmasked. It was a simple meal, and what she enjoyed most was being able to see other peoples faces.

While Hodges said she isnt comfortable going out to eat just yet, she said shes really looking forward to getting back to restaurants once vaccines become widespread across the state.

She also traveled to Anchorage recently, and said shes looking forward to more travel in the future.

Dr. Bruce Chandler, a medical officer with Anchorage Health Department, said that his work at the health department means hes always aware of which clusters of COVID-19 are going around the city, and that hyperawareness makes him extra cautious even though hes now fully vaccinated.

Weve still got a lot of COVID moving around through the community, he said. But I will say that probably for the last nine months, Ive been primarily living through Walmart and Fred Meyer curbside pickup, and really avoiding anything else. Now Ive got my courage up, and I can go into Costco and buy cat food and kitty litter.

A woman writes the date of a patient's second Pfizer-BioNtech COVID-19 vaccine on a sticker for them as a reminder at the Alaska Airlines Center in Anchorage on Saturday, Jan. 9, 2021. (Emily Mesner / ADN)

Chandler says hes an introvert, so in some ways, he hasnt missed too much over the last year.

Still: I felt a big sense of relief when I got the first shot, a potentially life-changing event, he said. Its been a very, very stressful year for many, many people. Getting vaccinated takes some of that stress away.

Although Chandler himself hasnt felt the need to dine in at a restaurant, he was asked recently whether a group of younger people who have all been vaccinated can feel good about going out for a pizza.

I think thats a reasonable thing for people to do, given how well the currently available vaccines protect against severe illness, he said.

Chandler said hes still waiting for the CDC to clarify whether their guidance applies to a workplace, or a health care institution, where all employees are fully vaccinated. His overall stance is for Alaskans to err on the careful side for a little while longer until more Alaskans are vaccinated and less virus is circulating.

Even as we return to regular life, its good to still be cautious, he said. Its not over yet, but were looking a lot better than we were in November.

The rest is here:

What can you do after getting the COVID-19 vaccine? Here's how Alaska's top public health experts are adjusting. - Anchorage Daily News

Posted in Covid-19 | Comments Off on What can you do after getting the COVID-19 vaccine? Here’s how Alaska’s top public health experts are adjusting. – Anchorage Daily News

Massachusetts COVID reopening plan enters into Phase 4 Monday; Heres what you need to know – MassLive.com

Posted: at 5:07 pm

Massachusetts will move into Step 1 of Phase 4 in the COVID-19 reopening plan on Monday, March 22, which allows for a range of previously closed businesses and venues to open under capacity restrictions.

Those restrictions are expected to be adjusted over time if Massachusetts sees favorable trends in coronavirus statistics.

The change comes as Massachusetts health officials labeled 20 cities and towns as at high risk for spreading the virus, an increase from the prior 14 communities listed, but still much lower the past numbers.

Fenway Park and the TD Garden in Boston along with Gillette Stadium in Foxborough and the nearly completed Polar Park in Worcester will be allowed to have fans in the stands under the first step of Phase 4.

Those stadiums along with other large entertainment venues will be allowed to open under a strict 12% capacity limit after submitting a plan to the Department of Public Health.

The newest change by the Baker administration states that on March 22 the gathering limits for public events will increase to 100 people indoors and 150 people outdoors.

Outdoor gatherings at private residents and in private backyards remains at a maximum of 25 people with indoor house gatherings also still remaining at 10 people.

Dance floors will also be permitted at weddings and other events only, and overnight summer camps will be allowed to operate this summer.

The Baker administration is allowing for exhibition and convention halls to open as long as the gathering limits and event protocols are followed.

Several businesses and parks still remain closed under the newest phase. Theme parks, amusement parks and indoor and outdoor water parks are closed still along with bars that are not providing seating for food services.

Ball pits, saunas, hot-tubs and steam rooms still remain closed along with dance clubs and nightclubs. Street festivals, road races and other festivals along with parades remain shut down.

The coronavirus travel restrictions for Massachusetts residents will also be eased on Monday. The travel order will be replaced with a travel advisory.

The travel advisory encourages, but does not require, residents entering or returning to Massachusetts to quarantine for 10 days if they have been out of the state for 24 hours or more.

Travelers who tested negative for COVID-19 up to three days before entering the Bay State and travelers who were fully vaccinated at least two weeks ago, as well as workers who commute into the state or leave the state for work, are exempt.

The advisory does not apply to anyone in the following categories:

Related Content:

More here:

Massachusetts COVID reopening plan enters into Phase 4 Monday; Heres what you need to know - MassLive.com

Posted in Covid-19 | Comments Off on Massachusetts COVID reopening plan enters into Phase 4 Monday; Heres what you need to know – MassLive.com

Many people who die of COVID-19 have the virus in their hearts – Science Magazine

Posted: at 5:07 pm

Small, dark purple spots show inflammatory cells invading the heart of a patient who died of COVID-19.

By Emma YasinskiMar. 17, 2021 , 12:00 AM

Sciences COVID-19 reporting is supported by the Heising-Simons Foundation.

Three-quarters of people who died of COVID-19 harbored the SARS-CoV-2 virus in their hearts, according to the most detailed study of cardiac tissue to date. Those people were also more likely than patients without cardiac invasion to experience abnormal heart rhythms before they died. The study offers insight into how the disease may damage the heartand how certain treatments may help.

The finding paints a really nice picture of the connection between the virus and heart problems, says Joseph Maleszewski, a cardiovascular pathologist at the Mayo Clinic who was not involved with the study.

Scientists have ample evidence of heart damage in COVID-19 patients. Some people, for example, show elevated levels of troponins, molecules released in the blood when the heart is injured. Others have experienced inflammation of the sac surrounding the heartand inflammation of the heart itself. But its been unclear whether these problems were caused by the SARS-CoV-2 virus attacking the heart directly, or the damage is due to an overactive immune response.

Part of the problem is that previous studies are mixed about whether SARS-CoV-2 can invade heart tissue. Many that havent found the virus use real-time polymerase chain reaction (RT-PCR), says James Stone, a cardiovascular pathologist at Massachusetts General Hospital. RT-PCR works by detecting viral RNA in tissue, then making many DNA copies of it. Once theres enough DNA, a molecule called a fluorescent tag can stick to it and shine to reveal its presence. But Stone says that heart tissue is often processed and preserved using chemicals like paraffin, which can break down the RNA and prevent detection to begin with.

So he and his team used another approach: in situ hybridization and NanoString transcriptomic profiling. Like RT-PCR, these techniques use special molecules to attach to and detect pieces of viral RNA, but they do so without having to make DNA copies first. The approach can identify viral RNA even after its broken into smaller pieces. The scientists also analyzed about 1000 pieces of heart tissuemore than 20 samples from each of the 41 patients they looked at. Thats double the number of samples per patient in most studies, Stone says.

SARS-CoV-2 was present in 30 of the hearts, the team reports today in Modern Pathology. And only those patients experienced new atrial fibrillations, fast and irregular heart rhythms, or early or extra heartbeats, compared with the other patients in the studya correlation Stone calls pretty phenomenal.

Still, its unclear whether the virus attacked the heart directly in these cases. Most of the infected cardiac cells were immune cells, which SARS-CoV-2 could have invaded elsewhere in the body before they traveled to the heart. Its also unclear whether the virusrather than the immune cells themselvesis causing the problems.

Regardless, the study may help explain why the steroid dexamethasone is so helpful to some patients. The drug was one of the first found to prevent deaths from severe COVID-19. It reduces inflammation, so it may have curbed the presence of SARS-CoV-2harboring immune cells in the heart, Stone says. Only 50% of the patients treated with dexamethasone had the virus in their hearts, compared with 90% of patients who were not on the drug.

But compared with large clinical trials, the number of patients in this new study is small, making it impossible to say that one drug protects the heart better than another, says Nicholas Hendren, a cardiology fellow at the University of Texas Southwestern Medical Center.

Still, Maleszewski says the new findings are a call to action. Scientists need to probe more cardiac tissue, he argues, not just to see how COVID-19 kills patients, but to figure out how it hurts the hearts of those that survive. The disease may, for example, create scar tissue that can cause cardiac problems down the line. Were starting to understand what COVID-19 does to patients when they have it, he says. Whats not clear is what happens later on.

Continue reading here:

Many people who die of COVID-19 have the virus in their hearts - Science Magazine

Posted in Covid-19 | Comments Off on Many people who die of COVID-19 have the virus in their hearts – Science Magazine

WHO thinks it knows where COVID-19 originated – Livescience.com

Posted: at 5:07 pm

After a months-long investigation, the World Health Organization (WHO) has found that wildlife farms in China are likely the source of the COVID-19 pandemic.

These wildlife farms, many of them in or around the southern Chinese province of Yunnan, were likely supplying animals to vendors at the Huanan Seafood Wholesale Market in Wuhan, where early cases of COVID-19 were discovered last year, Peter Daszak, a disease ecologist on the WHO team that traveled to China, told NPR. Some of these wild animals could have been infected with SARS-CoV-2 from bats in the area.

The WHO is expected to release its findings in a report in the coming weeks.

Related: 20 of the worst epidemics and pandemics in history

In January, a WHO team of experts traveled to China to probe how the deadly pandemic, which has now infected more than 120 million people and killed 2.6 million worldwide, first started, Live Science previously reported. A rash of conspiracy theories have been spread about the origin of the virus, including that the virus escaped from a Wuhan lab. Last month, the WHO investigators dismissed that explanation.

The general consensus among scientists was that the coronavirus was circulating in bats and hopped to humans, likely through an intermediate species. That's exactly what the WHO investigations found: The virus likely passed from bats in southern China to animals in wildlife farms, and then to humans.

The wildlife farms are part of a project that the Chinese government has been promoting for 20 years to lift rural populations out of poverty and close the rural-urban divide, according to Daszak and NPR.

"They take exotic animals, like civets, porcupines, pangolins, raccoon dogs and bamboo rats, and they breed them in captivity," Daszak told NPR.

But in February 2020, China shut down those farms, likely because the Chinese government thought that they were part of the transmission pathway from bats to humans, Daszak said. The government sent out instructions to farmers about how to bury, kill or burn the animals in a way that wouldn't spread disease, Daszak told NPR.

Many of these farms breed animals that can carry coronaviruses, including civets, cats and pangolins. Most are located in or near the Yunnan province in southern China, where scientists previously discovered a bat virus that's 96% similar to SARS-CoV-2, according to NPR. The WHO still doesn't know what animal carried the virus from bats to humans.

"I do think that SARS-CoV-2 first got into people in South China. Its looking that way," Daszak told NPR. The WHO also found evidence that these wildlife farms were supplying vendors at the Huanan Seafood Wholesale Market.

"China closes that pathway down for a reason," Daszak said. Namely, that they likely thought that this was the most likely path of transmission, which is also what the WHO report will conclude, he added.

You can read the whole story on NPR.

Originally published on Live Science.

Read the original here:

WHO thinks it knows where COVID-19 originated - Livescience.com

Posted in Covid-19 | Comments Off on WHO thinks it knows where COVID-19 originated – Livescience.com

MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation – PRNewswire

Posted: at 5:07 pm

"Responsiveness to customer needs is a core part of MagVenture DNA," says MagVenture SVP of Sales, Kerry Rome. "MagVenture is continuously striving to improve solutions to optimize the clinical practice of transcranial magnetic stimulation or TMS in short. In recent years, the clinical market for TMS has expanded at such a rapid pace that manufacturers are being challenged to keep pace with the technological requirements emerging with the exponential expansion in the demand for utilization. We've seen MagVenture drive an FDA clearance for the ultra-fast 'Theta Burst' TMS which has reduced treatment times for patients from 37 to just 3 minutes. Now, with the introduction of a remarkedly smooth solution to help TMS operators quickly and easily prepare patients for treatment, MagVenture is further improving the efficiency and experience of TMS for patients and operators alike," states Kerry Rome.

The latest improvement to the MagVenture TMS Therapy system, deemed the 'MagVenture Flow Arm', concerns the applicator 'coil'.The coil is essentially two very heavy spools of copper wire that produce and focus the magnetic fields for the non-invasive brain stimulation technique. The typically large and unwieldy coils, by necessity, have to be accurately positioned and held immobile over the brain target(s) during the TMS procedures. Over the past year, MagVenture product engineers and application experts, in close collaboration with MagVenture customers in the USA, Europe, Australia, and Asia, perfected a solution that vastly improves ease of use for MagVenture TMS operators to now, almost effortlessly, move and securely position TMS coils for non-invasive brain stimulation (TMS) procedures.

Kerry Rome goes on to add: "Throughout the R&D and testing phases for the Flow Arm project, the MagVenture organization here in the US has been waiting with much anticipation and, finally, we are super excited about the introduction of MagVenture's patent-pending 'Flow Arm' for TMS coil positioning. It's a game changer for TMS providers seeking optimal ease of use and efficiency in their clinical TMS services and, in context with the current COVID-19 pandemic, the improvements in the MagVenture reduced treatment/operator-patient interaction time is going to prove to be a big positive."

Transcranial Magnetic Stimulation is a technology that applies rapidly changing magnetic fields to stimulate specific areas in the brain. TMS has been available as a tool for non-invasive brain stimulation for more than three decades and is currently used extensively in clinical psychiatry, and for ongoing academic medical and translational neuroscience research. MagVenture TMS Therapy is FDA cleared as a treatment for major depressive disorder (MDD) and as an adjunct therapy treatment for obsessive-compulsive disorder (OCD). MagVenture TMS Therapy is an outpatient procedure with a well-tolerated safety profile with no systemic side effects. The most common side effects are headaches and nausea. MagVenture TMS Therapy has been clinically available in the USA since 2015 and is currently delivered at hospitals and psychiatric practices nationwide.

Contact details: Kerry Rome, Vice President Sales, MagVenture Inc., USA: 310 213 2697, email: [emailprotected]

MagVenture TMS Therapy FDA clearances: "Treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode and as an "adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD)".

MagVenture is a Danish medical device company specializing in non-invasive magnetic stimulation solutions for the clinical treatments and brain research. In 2018, MagVenture was the first TMS company to receive FDA clearance for Express TMS, reducing treatment time from the standard 37 minutes to just 3 minutes per session.

MagVenture A/S has over 25 years of experience within neuromodulation. From its headquarters in Denmark, MagVenture's products are manufactured and promoted worldwide through direct sales subsidiaries in the US, Brazil, Germany, the UK, and through an extensive global network of dedicated distributors in Europe, Asia, Middle East, and the Americas.

* Pat. EP 20214073.7 / US 63/125,594.

SOURCE MagVenture

Excerpt from:

MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation - PRNewswire

Posted in Tms | Comments Off on MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation – PRNewswire

Greenbrook to Commence Trading on NASDAQ – Business Wire

Posted: at 5:07 pm

TORONTO--(BUSINESS WIRE)--Greenbrook TMS Inc. (TSX: GTMS) (Greenbrook or the Company) is pleased to announce that its common shares have been approved for listing and trading in U.S. dollar currency on the NASDAQ Stock Market LLC (NASDAQ). Trading on the NASDAQ will commence at the start of trading on March 16, 2021 under the symbol GBNH. Greenbrooks common shares will continue trading on the Toronto Stock Exchange in Canadian dollar currency under the symbol GTMS.

The listing of our common shares on the NASDAQ marks a significant milestone in the history of our Company, commented Bill Leonard, President and Chief Executive Officer of Greenbrook. We believe that the NASDAQ listing will provide significant benefits, including increased visibility of the Company amongst investors, increased access to capital and potential for greater liquidity.

About Greenbrook TMS Inc.

Operating through 126 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 510,000 TMS treatments to over 14,000 patients struggling with depression.

Cautionary Note Regarding Forward-Looking Information

Certain information in this press release, including with respect to the trading of Greenbrooks common shares on the NASDAQ, constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as plans, targets, expects or does not expect, is expected, an opportunity exists, is positioned, estimates, intends, assumes, anticipates or does not anticipate or believes, or variations of such words and phrases or state that certain actions, events or results may, could, would, might, will or will be taken, occur or be achieved. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent managements expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the Risk Factors section of the Companys current annual information form available at http://www.sedar.com and http://www.sec.gov. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Link:

Greenbrook to Commence Trading on NASDAQ - Business Wire

Posted in Tms | Comments Off on Greenbrook to Commence Trading on NASDAQ – Business Wire

Axele Executive Named to SDCE 2021 Pros to Know – GlobeNewswire

Posted: at 5:07 pm

DALLAS, March 17, 2021 (GLOBE NEWSWIRE) -- Axele, LLC, a Transportation Management System (TMS) company, announces that Director of Strategy and Business Development, Ryan Camacho, has been named a 2021 Pro to Know. This prestigious award from Supply & Demand Chain Executive, the only publication covering the entire global supply chain, recognizes outstanding executives whose accomplishments leverage supply chains for competitive advantage.

Being named a Pro to Know is a testament to Ryans perfect execution of Axele TMSs vision, making the solution a one-stop-shop for small-to-midsized carriers that automates day-to-day operations and increases profits, said Ravi Ahuja, Founder & CEO, Axele. Our customers regularly compare the technology to that of an iPhone easy to use and delivering a tremendous amount of value. They feel like they have bought a $150,000 system for only dollars a day.

"While many companies have struggled to regain their footing as a result of COVID-19, this year's Pros to Know winners stepped up to the plate to deliver innovative solutions and programs in a time of crisis and need. These winners collaborated, optimized, developed, educated, and played a critical role in the survival and success of their company amid a global pandemic," says Marina Mayer, Editor-in-Chief of Supply & Demand Chain ExecutiveandFood Logistics. I am honored to recognize these individuals and teams and extend my utmost gratitude to everyone in the supply chain industry for their time, efforts, and innovations to keep our nation's supply chains afloat."

For the small-to-midsized truckload carrier, access to a comprehensive TMS has long been out of reach. Most legacy systems are either premise-based solutions requiring expensive hardware and an onsite IT support system or are priced unattainably. Axeles vision is to build a robust TMS with advanced integrations to load boards, ELDs, factoring companies, and back-end accounting systems and make it available through the cloud at an affordable price. No other vendor provides significant system advancements like optimization, artificial intelligence, automation, and more within their TMS at a cost attainable for small companies.

Ryan Camacho has worked for several high-profile logistic software companies, such as Oz Development, Descartes System Group, Kuebix, and Trimble. He has developed a tremendous amount of software and transportation industry expertise with many years in this space. He has held positions from the ground up to leadership positions, including customer support manager, software developer, implementation specialist, executive sales representative, senior sales engineer, and director of product management. At Axele, Ryan drives strategy and product evolution of the Axele Transportation Management System; the first SaaS-based TMS built specifically for the small-to-midsized full truckload carrier.

The 2021 Pros to Know award includes individuals and teams from software and service providers, consultancies and academia, trucking and transportation firms, professional development agencies, sourcing, and procurement divisions, and more, all who have helped supply chain clients and the supply chain community at large prepare to meet many of today'sand tomorrow'schallenges.

Go towww.sdcexec.com to view the complete list of all 2021 Pros to Know winners.

About Axele

Axele offers transportation management system (TMS) cloud software for truckload carriers leveraging decades of experience and insights into optimization and automation technology. Launched by Optym in 2020, Axele is the industry's first intelligent, connected solution, built specifically for small to mid-sized truckload carriers. Axele serves for-hire truckload operators and private fleets who haul general freight, dry van, flatbed, and refrigerated loads. The Axele TMS integrates with load boards, ELDs, market rates, maps, and accounting systems, to enable an owner-operator or carrier to find better loads, increase profits, and grow their business. For more information about Axele, go to http://www.axele.com.

AboutSupply & Demand Chain Executive

Supply & Demand Chain Executiveis the only supply chainpublication covering the entire global supply chain, focusing on trucking, warehousing, packaging, procurement, risk management, professional development, and more. Go towww.SDCExec.com.

Media Contact for Axele:Becky BoydMediaFirst PR(770) 642-2080 x 214Cell (404) 421-8497Becky@MediaFirst.Net

Visit link:

Axele Executive Named to SDCE 2021 Pros to Know - GlobeNewswire

Posted in Tms | Comments Off on Axele Executive Named to SDCE 2021 Pros to Know – GlobeNewswire

Neuro Wellness TMS Centers Of America In Coral Springs: Do You Have Obsessive Compulsive Behaviors And Thoughts? – TAPinto.net

Posted: at 5:07 pm

CORAL SPRINGS, FL Medical experts report that two percent of Americans develop obsessive-compulsive disorder (OCD), and half of them will experience chronic, severe symptoms that disrupt every aspect of their daily lives.

The disorder affects people of all ages and walks of life, and it occurs when a person gets caught in a cycle ofcompulsions and obsessions.

Most people have compulsive behaviors and/or obsessive thoughts at some point in their lives, but that does not mean that we all have some level of OCD.

Sibyl Simon, MD, and the team at Neuro Wellness TMS Centers of America can help you assess your behaviors and thoughts.

They offer comprehensive care for OCD, including medication alternatives for previously failed medications, psychotherapy, and alternative treatments for people whose symptoms dont improve with medication.

Read more about Neuro Wellness TMS Centers of Americas therapy for OCD here.

If you struggle with OCD and need a treatment that enhances your quality of life, call their office in Coral Springs, or book an appointment online.

Call Neuro Wellness TMS Centers of America in Coral Springs at 954.903.1323.

Or visit their website: neurowellnesstms.com

Read more:

Neuro Wellness TMS Centers Of America In Coral Springs: Do You Have Obsessive Compulsive Behaviors And Thoughts? - TAPinto.net

Posted in Tms | Comments Off on Neuro Wellness TMS Centers Of America In Coral Springs: Do You Have Obsessive Compulsive Behaviors And Thoughts? – TAPinto.net

Transcranial Magnetic Stimulators (TMS) Market 2021: Applications, Types and Growing Trends in Market, Gross Margin and Market Share 2027 – Cabell…

Posted: at 5:07 pm

Fort Collins, Colorado:The report, titled Transcranial Magnetic Stimulators (TMS) Market Size By Types, Applications, Segmentation, and Growth Global Analysis and Forecast to 2021-2027 first introduced the fundamentals of Transcranial Magnetic Stimulators (TMS): Definitions, Classifications, Applications, and Market Overview; Product specifications; Production method; Cost Structures, Raw Materials, etc. The report takes into account the impact of the novel COVID-19 pandemic on the Transcranial Magnetic Stimulators (TMS) market and also provides an assessment of the market definition as well as the identification of the top key manufacturers contrasting with the competitive landscape in terms of price, revenue, capacity, Import, Export, Transcranial Magnetic Stimulators (TMS) Market Size, Consumption, Gross, Gross Margin, Sales and Market Share. Quantitative analysis of the Transcranial Magnetic Stimulators (TMS) industry from 2015 to 2020 by region, type, application, and consumption assessment by region.

(Exclusive Offer: Flat 30% discount on this report)

Get | Download Sample Copy @ https://reportsglobe.com/download-sample/?rid=138063

The Following Companies are Major Contributors to the Transcranial Magnetic Stimulators (TMS) Market Research Report:

Transcranial Magnetic Stimulators (TMS) Market Segmentation:

Based on Type

Based on Application

Based on the Region:

North America (USA, Canada and Mexico) Europe (Germany, France, Great Britain, Russia and Italy) Asia Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia, etc.) Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria, and South Africa)

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=138063

The report includes Competitors Landscape:

? Main growth trends and forecasts by region and country? Major winning strategies followed by competitors? Who are the main competitors in this industry?? What is the potential of this industry over the expected term?? What are the factors driving the demand for Transcranial Magnetic Stimulators (TMS)?? Which opportunities will contribute to a significant spread of the market growth?? What regional and national regulations will hinder or stimulate the demand for Transcranial Magnetic Stimulators (TMS)?? What impact did covid-19 have on market growth?? Has the interruption in the supply chain caused changes in the entire value chain?

The scope of the report:

The Transcranial Magnetic Stimulators (TMS) Market Research Report is a comprehensive publication that aims to determine the financial outlook for the market. For the same reason, it offers a detailed understanding of the competitive landscape. It examines some of the key players, their leadership styles, their research and development status, and their expansion strategies.

The report also includes the product portfolios and the list of products in the pipeline. It provides a detailed explanation of advanced technology and the investments that have been made to upgrade existing technologies.

View market snapshot before purchasing @ https://reportsglobe.com/product/global-transcranial-magnetic-stimulators-tms-market-insight/

Some Points from TOC

Chapter 1 Market Overview

Chapter 2 Company Profiles

Chapter 3 Market Competition by Players

Chapter 4 Market Size Segment by Type

Chapter 5 Market Size Segment by Application

Chapter 6 North America by Country, Type, and Application

Chapter 7 Europe by country, type and application

Chapter 8 Asia Pacific by Region, Type, and Application

Chapter 9 South America by Country, Type and Application

Chapter 10 Middle East and Africa by Country, Type, and Application

Chapter 11 Research Findings and Conclusions

Chapter 12 Appendix

Request customization of the report @ https://reportsglobe.com/need-customization/?rid=138063

Customization of the Report:

Please contact us if you would like more information about the report. If you have any special requirements and would like customization, please let us know. We will then offer the report as you wish.

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Sarkari Results, Thrive Market Research

Continued here:

Transcranial Magnetic Stimulators (TMS) Market 2021: Applications, Types and Growing Trends in Market, Gross Margin and Market Share 2027 - Cabell...

Posted in Tms | Comments Off on Transcranial Magnetic Stimulators (TMS) Market 2021: Applications, Types and Growing Trends in Market, Gross Margin and Market Share 2027 – Cabell…